LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to pharmaceutical companies Pfizer and Eli Lilly.

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...

PORTLAND, OR, UNITED STATES, July 17, 2025 /EINPresswire.com/ -- The global anti-obesity drugs market, valued at $1,605.36 million in 2022, is projected to reach $4,439.34 million by 2032, expanding ...

The B.C. government is restricting the sales of two more diabetes drugs to people outside Canada amid rising demand for the ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...